



US005880103A

United States Patent [19]

[11] Patent Number: **5,880,103**

Urban et al.

[45] Date of Patent: **Mar. 9, 1999**

[54] **IMMUNOMODULATORY PEPTIDES**

5,695,770 12/1997 Raychaudhuri et al. 424/278.1
5,703,055 12/1997 Felgner et al. 514/44
5,709,860 1/1998 Raychaudhuri et al. 424/184.1

[75] Inventors: **Robert Glen Urban**, Cambridge;
Roman M. Chicz, Jamaica Plain, both
of Mass.; **Dario A. A. Vignali**,
Rainham, United Kingdom; **Mary**
Lynne Hedley, Somerville, Mass.;
Lawrence J. Stern, Arlington, Mass.;
Jack L. Strominger, Lexington, Mass.

FOREIGN PATENT DOCUMENTS

WO 94/21680 9/1994 WIPO .

OTHER PUBLICATIONS

[73] Assignee: **President and Fellows of Harvard
College**, Cambridge, Mass.

Kriegler, Eurakytotic Control Elements, *Gene Transfer and
Expression A Laboratory Manual*, W.H. Freeman and Com-
pany, New York (1991) pp. 3-22.

[21] Appl. No.: **488,379**

Felgner and Rhodes, Gene Therapeutics, Nature
349:351-352, 1991.

[22] Filed: **Jun. 7, 1995**

Kriegler, Vectors, *Gene Transfer and Expression A Labora-
tory Manual*, W.H. Freeman and Company, New York
(1991) pp. 23-61.

Related U.S. Application Data

Kriegler, DNA Transfer, *Gene Transfer and Expression A
Laboratory Manual*, W.H. Freeman and Company, New
York (1991) pp. 96-102.

[60] Division of Ser. No. 77,255, Jun. 15, 1993, which is a
continuation-in-part of Ser. No. 925,460, Aug. 11, 1992,
abandoned.

Jin et al., "Human T Cell Response to the Surface Antigen
of Hepatitis B Virus (HBsAg)," *Journal of Experimental
Medicine*, 168:293-306, 1988.

[51] **Int. Cl.**⁶ **A01N 43/04**; C12N 7/01;
C12N 15/09; C12N 15/12

Adorini et al., Exogenous Peptides Compete for the Presen-
tation of Endogenous Antigens to Major Histocompatibility
Complex Class II-restricted T Cells, *Immunology Today*
11:945-948, 1991.

[52] **U.S. Cl.** **514/44**; 424/93.1; 424/93.2;
424/93.21; 435/172.3; 435/172.4; 435/235.1;
435/320.1; 435/325; 514/2; 530/300; 536/23.1;
536/23.4; 536/23.5; 536/23.92; 935/23;
935/32; 935/34

Adorini and Nagy, Peptide Competition for Antigen Presen-
tation, *Immunology Today* 11:21-24, 1990.

[58] **Field of Search** 424/93.1, 93.2,
42493.21; 514/44, 2; 435/172.1, 172.4,
235.1, 320.1, 325; 530/300; 536/23.1, 23.4,
23.5, 23.72; 935/23, 32, 37

Adorini et al., Competition for Antigen Presentation in
Living Cells Involves Exchange of Peptides Bound by Class
II MHC Molecules, *Nature* 342:800-803, 1989.

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,478,823 10/1984 Sanderson 424/194.1
4,681,760 7/1987 Fathman 424/154.1
5,130,297 7/1992 Sharma et al. 514/8
5,580,859 12/1996 Felgner et al. 514/44
5,589,466 12/1996 Felgner et al. 514/44
5,591,823 1/1997 Hung et al. 530/350
5,593,972 1/1997 Weiner et al. 514/44
5,662,896 9/1997 Barber et al. 424/93.2
5,670,153 9/1997 Weiner et al. 424/189.1

Chicz et al., Predominant Naturally Processed Peptides
Bound to HLA-DR1 are Derived from MHC-related Mol-
ecules and are heterogeneous in Size, *Nature* 358:764-768,
1992.

Rosen et al., "Dictionary of Immunology" published 1989
by Stockton Press (N.Y.), p. 23.

Sette et al., Random Association Between the Peptide Rep-
ertoire of A2.1 Class I and Several Different DR Class II
Molecules, *Journal of Immunology* 147:3893-3900, 1991.

Urban et al., Biochemical Analysis of Naturally Processed
Peptides Bound to Human Class II Molecules, *J. Cell.
Biochem., Keystone Symposia on Molecular & Cellular
Biology*, Supplement 160, 1992, p. 41:0262.